Researchers have identified an enzyme called IDOL as a potential target for Alzheimer's disease treatment. Removing IDOL from neurons significantly reduced amyloid plaques in laboratory studies. This also improved brain processes related to resilience and communication between cells.
The Indiana University School of Medicine conducted the research. Their findings suggest a new strategy for combating Alzheimer's. Current treatments, like lecanemab and donanemab, focus on clearing amyloid plaque buildup. These treatments slow the disease's progression.
Targeting IDOL could offer a different approach. It may reduce plaques and enhance communication between brain cells. It could also support healthy lipid metabolism. Enzymes are good drug targets because their active sites allow for precise drug design with fewer side effects.
The study involved creating two animal models of Alzheimer's disease. Researchers deleted the IDOL gene in different brain cell types. They expected microglia, brain immune cells, to show the most significant changes. Microglia are primary producers of IDOL and remove harmful materials.
However, removing IDOL from neurons produced the most notable effects. This action lowered plaque levels. It also reduced levels of apolipoprotein E (APOE), a protein linked to Alzheimer's disease. APOE4 is a major genetic risk factor for late-onset Alzheimer's. It also regulates lipid metabolism in the brain.
Researchers observed increased levels of receptors that regulate APOE and amyloid plaques after IDOL removal. These receptors are crucial for neuron communication and lipid metabolism. Activating a related pathway could increase resilience to cognitive decline, even with substantial plaque accumulation. This could provide multiple therapeutic benefits by reducing amyloid burden and enhancing neuroprotective effects.
Related stories
Dreaming May Deplete Brain Energy Despite Increased Fuel Supply
New research indicates that dreaming during REM sleep may consume significant brain energy, with neuronal energy levels dropping despite an increase in the brain's fuel supply.
Tirzepatide May Activate Calorie-Burning Brown Fat
A mouse study suggests tirzepatide, sold as Mounjaro and Zepbound, may activate calorie-burning brown fat, offering a new understanding of its metabolic benefits.
ADHD and Autism Diagnoses Show Shifting Demographics in Denmark
A large Danish study found that children diagnosed with ADHD or autism now more closely resemble the general population, suggesting broader identification rather than only an increase in underlying conditions.